Skip to main content
Erschienen in: Rheumatology International 4/2015

01.04.2015 | Original Article - Observational Research

Risk factors for cataracts in systemic lupus erythematosus (SLE)

verfasst von: Khaled Alderaan, Vuk Sekicki, Laurence S. Magder, Michelle Petri

Erschienen in: Rheumatology International | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Cataract is the most common ocular damage in systemic lupus erythematosus (SLE). We analyzed data from the Hopkins Lupus Cohort longitudinally to identify the factors that predict onset of cataract prior to 60 years of age. The Hopkins Lupus Cohort is a clinical cohort of patients with SLE seen quarterly. This analysis was based on the follow-up experience prior to age 60 of 2,109 SLE patients who had not had a cataract prior to cohort entry. Patients saw their ophthalmologist every 6 months. Cataract was defined by the SLICC/American College of Rheumatology Damage Index. The rate of incident cataract was calculated in subsets of the follow-up defined by patient characteristics and history. Multivariable logistic regression models were fit to identify predictors of cataract while controlling for potential confounding variables. The analysis was based on 11,887 persons-years of follow-up, with median follow-up time of 4.1 years per patient. The incidence of cataract was 13.2/1,000 persons-years. Adjusting for other predictors, a cumulative prednisone dose equivalent to 10 mg/day for 10 years was a strong predictor of cataract (RR = 2.9, P = 0.0010). Disease activity measured by SELENA–SLEDAI (P = 0.0004) and higher systolic blood pressure (P = 0.0003) were associated with cataract. Duration of SLE, diabetes mellitus, smoking, cholesterol, renal involvement, immunological profile and medication history other than prednisone were not associated with cataract. Cataract development in SLE patients is multifactorial with prednisone, systolic blood pressure and disease activity all playing a role.
Literatur
1.
Zurück zum Zitat Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–851PubMedCentralPubMed Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–851PubMedCentralPubMed
2.
Zurück zum Zitat Leske MC, Chylack LT Jr, Wu SY (1991) The lens opacities case–control study. Risk factors for cataract. Arch Ophthalmol 109:244–251CrossRefPubMed Leske MC, Chylack LT Jr, Wu SY (1991) The lens opacities case–control study. Risk factors for cataract. Arch Ophthalmol 109:244–251CrossRefPubMed
3.
Zurück zum Zitat Hiller R, Sperduto RD, Ederer F (1986) Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol 124:916–925PubMed Hiller R, Sperduto RD, Ederer F (1986) Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol 124:916–925PubMed
4.
Zurück zum Zitat Kanthan GL, Wang JJ, Rochtchina E, Tan AG, Lee A, Chia EM, Mitchell P (2008) Ten-year incidence of age-related cataract and cataract surgery in an older Australian population. The Blue Mountains Eye Study. Ophthalmology 115:808–814CrossRefPubMed Kanthan GL, Wang JJ, Rochtchina E, Tan AG, Lee A, Chia EM, Mitchell P (2008) Ten-year incidence of age-related cataract and cataract surgery in an older Australian population. The Blue Mountains Eye Study. Ophthalmology 115:808–814CrossRefPubMed
5.
Zurück zum Zitat West SK, Valmadrid CT (1995) Epidemiology of risk factors for age-related cataract. Surv Ophthalmol 39:323–334CrossRefPubMed West SK, Valmadrid CT (1995) Epidemiology of risk factors for age-related cataract. Surv Ophthalmol 39:323–334CrossRefPubMed
6.
Zurück zum Zitat Mares JA, Voland R, Adler R, Tinker L, Millen AE, Moeller SM, Blodi B, Gehrs KM, Wallace RB, Chappell RJ, Neuhouser ML, Sarto GE, CAREDS Group (2010) Healthy diets and the subsequent prevalence of nuclear cataract in women. Arch Ophthalmol 128:738–749CrossRefPubMedCentralPubMed Mares JA, Voland R, Adler R, Tinker L, Millen AE, Moeller SM, Blodi B, Gehrs KM, Wallace RB, Chappell RJ, Neuhouser ML, Sarto GE, CAREDS Group (2010) Healthy diets and the subsequent prevalence of nuclear cataract in women. Arch Ophthalmol 128:738–749CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808CrossRef Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808CrossRef
8.
Zurück zum Zitat Carli L, Tani C, Querci F, Della Rossa A, Vagnani S et al (2013) Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol 32:1071–1073CrossRefPubMed Carli L, Tani C, Querci F, Della Rossa A, Vagnani S et al (2013) Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol 32:1071–1073CrossRefPubMed
9.
Zurück zum Zitat Soo MP, Chow SK, Tan CT, Nadior N, Yeap SS, Hoh HB (2000) The spectrum of ocular involvement in patients with systemic lupus erythematosus without ocular symptoms. Lupus 9:511–514CrossRefPubMed Soo MP, Chow SK, Tan CT, Nadior N, Yeap SS, Hoh HB (2000) The spectrum of ocular involvement in patients with systemic lupus erythematosus without ocular symptoms. Lupus 9:511–514CrossRefPubMed
10.
Zurück zum Zitat Sitaula R, Shah DN, Singh D (2011) The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal. Ocul Immunol Inflamm 19:422–425CrossRef Sitaula R, Shah DN, Singh D (2011) The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal. Ocul Immunol Inflamm 19:422–425CrossRef
11.
Zurück zum Zitat Yap EY, Au Eong KG, Fong KY, Howe HS, Boey ML et al (1998) Ophthalmic manifestations in Asian patients with systemic lupus erythematosus. Singapore Med J 39:557–559PubMed Yap EY, Au Eong KG, Fong KY, Howe HS, Boey ML et al (1998) Ophthalmic manifestations in Asian patients with systemic lupus erythematosus. Singapore Med J 39:557–559PubMed
12.
Zurück zum Zitat Fraga MM, Len CA, Santos Finamor LP, Matos KT, Muccioli C et al (2011) Ocular changes due to the treatment of juvenile systemic lupus erythematosus. Rev Bras Reumatol 51:554–557CrossRefPubMed Fraga MM, Len CA, Santos Finamor LP, Matos KT, Muccioli C et al (2011) Ocular changes due to the treatment of juvenile systemic lupus erythematosus. Rev Bras Reumatol 51:554–557CrossRefPubMed
13.
Zurück zum Zitat Al-Mayouf SM, Al-Hemidan AI (2003) Ocular manifestations of systemic lupus erythematosus in children. Saudi Med J 24:964–966 Al-Mayouf SM, Al-Hemidan AI (2003) Ocular manifestations of systemic lupus erythematosus in children. Saudi Med J 24:964–966
14.
Zurück zum Zitat Chavez Villa M, Romero Diaz J, Recillas Gispert C, Lizana C, Cardenas F et al (2011) Risk factors associated with cataracts in systemic lupus erythematosus patients. An inception-Cohort Study [abstract]. Arthritis Rheum 63(Suppl 10):2272 Chavez Villa M, Romero Diaz J, Recillas Gispert C, Lizana C, Cardenas F et al (2011) Risk factors associated with cataracts in systemic lupus erythematosus patients. An inception-Cohort Study [abstract]. Arthritis Rheum 63(Suppl 10):2272
15.
Zurück zum Zitat Fong KY, Thumboo J, Koh ET, Chng HH, Leong KH et al (1997) Systemic Lupus Erythematosus: initial manifestations and clinical features after 10 years of disease. Ann Acad Med Singapore 26:278–281PubMed Fong KY, Thumboo J, Koh ET, Chng HH, Leong KH et al (1997) Systemic Lupus Erythematosus: initial manifestations and clinical features after 10 years of disease. Ann Acad Med Singapore 26:278–281PubMed
16.
Zurück zum Zitat Klejnberg T, Moraes Junior HV (2006) Ophthalmological alterations in outpatients with systemic lupus erythematosus. Arq Bras Oftalmol 69:233–237CrossRefPubMed Klejnberg T, Moraes Junior HV (2006) Ophthalmological alterations in outpatients with systemic lupus erythematosus. Arq Bras Oftalmol 69:233–237CrossRefPubMed
17.
Zurück zum Zitat Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRefPubMed Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRefPubMed
18.
Zurück zum Zitat Shah M, Chaudhari S, McLaughlin TP, Kan HJ, Bechtel B et al (2013) Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus Erythematosus. Clin Ther 35:486–497CrossRefPubMed Shah M, Chaudhari S, McLaughlin TP, Kan HJ, Bechtel B et al (2013) Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus Erythematosus. Clin Ther 35:486–497CrossRefPubMed
19.
Zurück zum Zitat Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119–1124CrossRefPubMed Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119–1124CrossRefPubMed
20.
Zurück zum Zitat Skalka HW, Prchal JT (1980) Effect of corticosteroids on cataract formation. Arch Ophthalmol 98:1773–1777CrossRefPubMed Skalka HW, Prchal JT (1980) Effect of corticosteroids on cataract formation. Arch Ophthalmol 98:1773–1777CrossRefPubMed
21.
Zurück zum Zitat Limaye SR, Pillai S, Tina LU (1988) Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol 20:225–227PubMed Limaye SR, Pillai S, Tina LU (1988) Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol 20:225–227PubMed
22.
Zurück zum Zitat Black RL, Oglesby RB, von Sallmann L, Bunim JJ (1960) Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 174:166–171CrossRefPubMed Black RL, Oglesby RB, von Sallmann L, Bunim JJ (1960) Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 174:166–171CrossRefPubMed
23.
Zurück zum Zitat Gupta V, Awasthi N, Wagner BJ (2007) Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells. Invest Ophthalmol Vis Sci 48:1724–1734CrossRefPubMedCentralPubMed Gupta V, Awasthi N, Wagner BJ (2007) Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells. Invest Ophthalmol Vis Sci 48:1724–1734CrossRefPubMedCentralPubMed
24.
25.
Zurück zum Zitat Gladman DD, Ibañez D, Ruiz I, Urowitz MB (2013) Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 40:630–633CrossRefPubMed Gladman DD, Ibañez D, Ruiz I, Urowitz MB (2013) Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 40:630–633CrossRefPubMed
26.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Winchester RJ et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Winchester RJ et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed
27.
Zurück zum Zitat Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725 Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725
28.
Zurück zum Zitat Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550–2558CrossRefPubMed Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550–2558CrossRefPubMed
29.
Zurück zum Zitat American Diabetes Association (2008) Diagnosis and classification of diabetes mellitus. Diabetes Care 31(Suppl 1):S55–S60CrossRef American Diabetes Association (2008) Diagnosis and classification of diabetes mellitus. Diabetes Care 31(Suppl 1):S55–S60CrossRef
30.
Zurück zum Zitat Pincus T, Castrejón I, Sokka T (2011) Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol 29:S130–S138PubMed Pincus T, Castrejón I, Sokka T (2011) Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol 29:S130–S138PubMed
31.
Zurück zum Zitat Waszczykowska A, Goś R, Waszczykowska E, Dziankowska-Bartkowiak B, Jurowski P (2013) Prevalence of ocular manifestations in systemic sclerosis patients. Arch Med Sci 30:1107–1113CrossRef Waszczykowska A, Goś R, Waszczykowska E, Dziankowska-Bartkowiak B, Jurowski P (2013) Prevalence of ocular manifestations in systemic sclerosis patients. Arch Med Sci 30:1107–1113CrossRef
32.
Zurück zum Zitat Jobling AI, Augusteyn RC (2002) What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 85:61–75CrossRefPubMed Jobling AI, Augusteyn RC (2002) What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 85:61–75CrossRefPubMed
33.
Zurück zum Zitat Schaumberg DA, Glynn RJ, Christen WG, Ajani UA, Stürmer T et al (2001) Prospective study of blood pressure and risk of cataract in men. Ann Epidemiol 11:104–110CrossRefPubMed Schaumberg DA, Glynn RJ, Christen WG, Ajani UA, Stürmer T et al (2001) Prospective study of blood pressure and risk of cataract in men. Ann Epidemiol 11:104–110CrossRefPubMed
34.
Zurück zum Zitat Richter GM, Torres M, Choudhury F, Azen SP, Varma R; Los Angeles Latino Eye Study Group (2012) Risk factors for cortical, nuclear, posterior subcapsular, and mixed lens opacities: the Los Angeles Latino Eye Study. Ophthalmology 119:547–554CrossRef Richter GM, Torres M, Choudhury F, Azen SP, Varma R; Los Angeles Latino Eye Study Group (2012) Risk factors for cortical, nuclear, posterior subcapsular, and mixed lens opacities: the Los Angeles Latino Eye Study. Ophthalmology 119:547–554CrossRef
35.
Zurück zum Zitat Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR et al (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (Clinical Research Ed.) 321:412–419CrossRef Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR et al (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (Clinical Research Ed.) 321:412–419CrossRef
36.
Zurück zum Zitat Leske MC, Wu SY, Nemesure B, Hennis A, Barbados Eye Studies Group (2002) Risk factors for incident nuclear opacities. Ophthalmology 109:1303–1308CrossRefPubMed Leske MC, Wu SY, Nemesure B, Hennis A, Barbados Eye Studies Group (2002) Risk factors for incident nuclear opacities. Ophthalmology 109:1303–1308CrossRefPubMed
37.
Zurück zum Zitat Lu ZQ, Sun WH, Yan J, Jiang TX, Zhai SN, Li Y (2012) Cigarette smoking, body mass index associated with the risks of age-related cataract in male patients in northeast China. Int J Ophthalmol 5:317–322PubMedCentralPubMed Lu ZQ, Sun WH, Yan J, Jiang TX, Zhai SN, Li Y (2012) Cigarette smoking, body mass index associated with the risks of age-related cataract in male patients in northeast China. Int J Ophthalmol 5:317–322PubMedCentralPubMed
38.
Zurück zum Zitat Christen WG, Manson JE, Seddon JM, Glynn RJ, Buring JE et al (1992) A prospective study of cigarette smoking and risk of cataract in men. JAMA 268:989–993CrossRefPubMed Christen WG, Manson JE, Seddon JM, Glynn RJ, Buring JE et al (1992) A prospective study of cigarette smoking and risk of cataract in men. JAMA 268:989–993CrossRefPubMed
39.
Zurück zum Zitat Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rochtchina E et al (2002) Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol 155:997–1006CrossRefPubMed Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rochtchina E et al (2002) Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol 155:997–1006CrossRefPubMed
Metadaten
Titel
Risk factors for cataracts in systemic lupus erythematosus (SLE)
verfasst von
Khaled Alderaan
Vuk Sekicki
Laurence S. Magder
Michelle Petri
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 4/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3129-5

Weitere Artikel der Ausgabe 4/2015

Rheumatology International 4/2015 Zur Ausgabe

Review Article - Pathology reviews

Role of osteopontin in rheumatoid arthritis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.